on Vita 34 AG (ETR:V3V)
FamiCord AG Secures ArThec as New CDMO Client
FamiCord AG has announced a framework agreement with ArThec S.A., expanding its CDMO business. The deal involves developing advanced regenerative medicine technologies, aiming to improve treatments for joint diseases. This collaboration highlights FamiCord's growing strategic focus on CDMO services.
The agreement is projected to generate approximately EUR 0.7 million in revenue within a year, contingent on project progress, and offers an attractive profit margin. This partnership underscores FamiCord's role as a reliable CDMO service provider. CEO Jakub Baran views this as crucial for stabilizing the company's revenue streams and supporting long-term business sustainability.
The collaboration also opens opportunities for future projects in regenerative medicine and advanced therapies. FamiCord continues negotiations with additional potential clients, indicating ongoing expansion in the CDMO sector.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Vita 34 AG news